As long as the exact mechanism by which PDE5 inhibitors may improve LUTS remains unclear, it is difficult to determine the specific subset of BPH patients who will benefit from the combination of PDE5-I with agents commonly administered to benign prostatic hyperplasia patients. This evidence concerns the gene PDE5A and benign prostatic hyperplasia.